SeP-neutralizing Ab improved intrahepatic levels of total cholesterol and triglycerides in KKAy mice, suggesting a therapeutic benefit of SeP-neutralizing Ab for fatty liver disease as well as type 2 diabetes. Here, SELENOP is linked to type 2 diabetes mellitus.